Who is sponsoring NCT04132687?

NCT04132687 is sponsored by Chinese University of Hong Kong.

What drugs are being tested in NCT04132687?

Interventions in NCT04132687: autologous blood patch therapy.

What condition does NCT04132687 study?

NCT04132687 studies Autologous Blood Patch Therapy.

Is NCT04132687 still recruiting?

NCT04132687 is currently status unknown. Last updated 22 October 2019.

Last reviewed 2019-10-22 · How we verify

NCT04132687: ABPT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ABPT in Secondary Pneumothorax With Persistent Airleak Study

Status unknown NA Last updated 22 October 2019

What this trial tests

NA trial testing autologous blood patch therapy in Autologous Blood Patch Therapy in 35 participants. Status unknown.

Timeline

10 September 2019

Primary endpoint
30 July 2020

30 October 2020

Quick facts

Lead sponsor	Chinese University of Hong Kong
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	10 September 2019
Primary completion	30 July 2020
Estimated completion	30 October 2020
Sites	2 locations across Hong Kong

Drugs / interventions tested

autologous blood patch therapy

Conditions studied

Autologous Blood Patch Therapy — all drugs for Autologous Blood Patch Therapy →

Sponsor

Chinese University of Hong Kong

Who can join

18 and older, any sex, with Autologous Blood Patch Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective clinical trial with each patient serving as his/her own control. Patients will be recruited in three different Hong Kong hospital. All patients at the recruitment centers with ongoing air leak after ≥ 3 days from the initial diagnosis of SSP will be approached by site investigators. Patient consented to enter the study will have their rate of air leak measured on day 3 (or after if enrolled later than day 3) byreplacing the conventional chest drain system with the digital chest drainage device (Thopaz). Autologous blood patch will be instilled if the patient still has persistent air leak on day 5 of chest drain insertion ( or 48 hours of electronic chest drain measurement of airleak).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04132687 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
Last refreshed: 22 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04132687.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing